Shire Gains Neonate Product With Premacure Acquisition
By Catherine Shaffer
Tuesday, March 12, 2013
Shire plc will gain a foothold in neonatology with its acquisition of Premacure AB, of Uppsala, Sweden. Premacure is developing a protein replacement therapy for the prevention of retinopathy of prematurity (ROP), a rare eye disease affecting about 14,000 to 16,000 preterm infants in the U.S. each year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.